GO:0048487 beta-tubulin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048487 beta-tubulin binding is a molecular function defined as binding to the microtubule constituent protein beta-tubulin.
• Beta-tubulin binding underlies microtubule dynamics, mitotic spindle function, and intracellular transport, and is a direct target of tubulin-binding agents used in cancer therapy.
• The colchicine-binding site and the exchangeable GTP site on beta-tubulin are key structural determinants of beta-tubulin binding.
• Beta-tubulin isotypes, especially beta-III tubulin (TUBB3), influence drug binding and neurotoxicity, with beta-III tubulin levels determining the neurotoxicity of the colchicine-site agent indibulin.
• Mutations in beta-tubulin can alter paclitaxel binding and contribute to chemotherapy resistance.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of beta-tubulin binding-related genes in disease and drug-response research.
Description
GO:0048487 beta-tubulin binding is a molecular function term in the Gene Ontology that describes the binding of a protein or molecule to beta-tubulin, the microtubule constituent protein. Beta-tubulin is a core subunit of the alpha/beta-tubulin heterodimer that polymerizes into microtubules, and proteins that bind beta-tubulin participate in microtubule regulation, cytoskeletal organization, and drug interactions. The term is therefore central to understanding how cells control microtubule dynamics and how tubulin-binding agents exert their effects. The colchicine-binding site of beta-tubulin was characterized as a key ligand-binding pocket on the protein, and the exchangeable GTP binding site of the beta-subunit has been studied in both normal and disease contexts. These structural features make beta-tubulin binding a focal point for pharmacology and cell biology. Beta-tubulin binding is relevant to cancer research because tubulin-binding agents such as taxanes and vinca alkaloids are widely used chemotherapeutics, and beta-tubulin isotype composition can influence drug response. Computational and biochemical studies have mapped how ligands such as cabazitaxel and paclitaxel interact with different human beta-tubulin isotypes and with mutant beta-tubulin. In addition, beta-tubulin binding proteins such as tau interact with neuronal-specific beta-tubulin isotypes, linking this molecular function to neurodegeneration and microtubule stability. For researchers, GO:0048487 provides a precise annotation target for classifying proteins that directly associate with beta-tubulin, whether as structural regulators, motors, or pharmacological ligands.
beta-tubulin binding At A Glance
| GO ID | GO:0048487 |
|---|---|
| GO term | beta-tubulin binding |
| Ontology | molecular_function |
| Synonym | beta tubulin binding |
| Major function | Binding to the microtubule constituent protein beta-tubulin |
| Definition source | QuickGO definition |
| Related ligands | Colchicine-site binders, taxanes, GTP, and other microtubule-targeting agents |
| Disease relevance | Cancer drug response, chemotherapy resistance, and neurotoxicity |
| Research methods | Binding assays, molecular dynamics, CRISPR models, and structural biology |
What Is GO:0048487?
In the Gene Ontology, GO:0048487 beta-tubulin binding is defined as binding to the microtubule constituent protein beta-tubulin. It is a molecular_function term, meaning it describes an activity performed by a gene product at the molecular level rather than a biological process or cellular component. The synonym beta tubulin binding is used interchangeably. This term captures direct physical interactions with beta-tubulin, including binding to its colchicine site, its exchangeable GTP site, or other surfaces that regulate microtubule assembly and stability.
Why Is beta-tubulin binding Important in Cell Biology?
GO:0048487 beta-tubulin binding is important because beta-tubulin is a fundamental building block of microtubules, and proteins or compounds that bind beta-tubulin can directly modulate microtubule dynamics, cell division, and intracellular transport. This molecular function is exploited by major classes of anticancer drugs, and beta-tubulin isotype expression and mutations can alter drug binding and clinical response. Understanding beta-tubulin binding therefore informs both basic cytoskeletal biology and therapeutic development.
• Beta-tubulin binding is central to microtubule dynamics and mitotic spindle assembly.
• The colchicine-binding site on beta-tubulin is a validated drug target for tubulin-binding agents.
• Beta-III tubulin levels determine neurotoxicity induced by the colchicine-site binding agent indibulin.
• Beta-tubulin isotype composition is a predictive factor in patients receiving tubulin-binding agents.
• Mutations in beta-tubulin can change paclitaxel binding and contribute to chemotherapy resistance.
• The exchangeable GTP binding site of beta-tubulin is altered in Alzheimer disease brain tissue.
• Tau repeat region R2 binds neuronal-specific beta-tubulin isotypes with differential affinity.
• Covalent binding of zoxamide to beta-tubulin of Botrytis cinerea illustrates the fungicidal relevance of this function.
• Computational studies of cabazitaxel and paclitaxel binding to beta-tubulin isotypes guide drug design.
• CRISPR-based models allow causal testing of beta-tubulin binding genes in cancer and neurodegeneration.
Molecular Mechanism of beta-tubulin binding
Beta-tubulin as the binding substrate
In simple terms: Beta-tubulin is the protein that other molecules stick to when this GO term is used.
Beta-tubulin is one of the two subunits of the alpha/beta-tubulin heterodimer that polymerizes into microtubules. The colchicine-binding site of beta-tubulin has been analyzed as a key ligand-binding pocket. The exchangeable GTP binding site of the beta-subunit is another functionally important region that has been studied in brain tubulin. These structural features define the surfaces through which beta-tubulin binding occurs.
Colchicine-site and taxane-site interactions
In simple terms: Different drugs bind beta-tubulin at different pockets, changing how microtubules behave.
Colchicine-site binding agents interact with a specific pocket on beta-tubulin, and beta-III tubulin levels determine the neurotoxicity induced by the colchicine-site binding agent indibulin. Taxanes such as cabazitaxel and paclitaxel bind beta-tubulin through distinct modes that have been modeled for different human beta-tubulin isotypes. Molecular simulations of paclitaxel binding to mutant beta-tubulin provide insights into chemotherapy resistance.
Isotype-specific binding
In simple terms: Different beta-tubulin versions bind partners with different strengths.
Human beta-tubulin isotypes differ in sequence and in their binding modes with ligands such as cabazitaxel. Tau repeat region R2 shows differential binding affinity with neuronal-specific beta-tubulin isotypes. Beta-III tubulin is a predictive factor in patients receiving tubulin-binding agents, indicating that isotype composition affects drug interactions.
Covalent and non-covalent binding modes
In simple terms: Some binders attach permanently, others only temporarily.
Zoxamide binds covalently to beta-tubulin of Botrytis cinerea, as revealed by molecular insights into covalent binding. In contrast, many tubulin-binding agents interact non-covalently with beta-tubulin pockets. These distinct binding modes influence the duration and reversibility of microtubule perturbation.
GTP site and nucleotide-dependent regulation
In simple terms: GTP binding at the beta-tubulin exchangeable site affects how beta-tubulin behaves.
The exchangeable GTP binding site of the beta-subunit of brain tubulin has been examined in Alzheimer disease, linking nucleotide-site occupancy to disease-related changes. This site is distinct from the colchicine and taxane pockets and contributes to the regulation of beta-tubulin function.
Key Genes Involved in GO:0048487 beta-tubulin binding
The following genes and proteins are directly relevant to beta-tubulin binding based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TUBB | Beta-tubulin subunit of microtubules | Core substrate for GO:0048487 beta-tubulin binding |
| TUBB3 | Neuronal beta-III tubulin isotype | Beta-III tubulin levels determine indibulin neurotoxicity |
| TUBB2B | Beta-tubulin isotype | Isotype-specific ligand binding modes studied computationally |
| TUBB4A | Beta-tubulin isotype | Beta-tubulin isotype context for drug binding |
| TUBB1 | Beta-tubulin isotype | Contributes to beta-tubulin isotype diversity |
| MAPT | Tau microtubule-associated protein | Tau repeat R2 binds neuronal beta-tubulin isotypes |
| TUBB (mutant) | Mutant beta-tubulin | Paclitaxel binding to mutant beta-tubulin and resistance |
| TUBB (Botrytis cinerea) | Fungal beta-tubulin | Covalent zoxamide binding target |
| TUBB (colchicine site) | Colchicine-binding pocket of beta-tubulin | Characterized as a ligand-binding site |
| TUBB (GTP site) | Exchangeable GTP binding site of beta-subunit | Studied in Alzheimer disease brain tubulin |
| TUBB (cabazitaxel target) | Beta-tubulin ligand pocket | DFT and MD studies of cabazitaxel binding |
| TUBB (indibulin target) | Colchicine-site binding target | Indibulin neurotoxicity depends on beta-III tubulin |
| TUBB (paclitaxel target) | Taxane binding site | Mutant beta-tubulin simulations for resistance |
| TUBB (zoxamide target) | Fungal beta-tubulin | Covalent binding insights |
| TUBB (tau partner) | Neuronal beta-tubulin isotype | Differential tau R2 binding affinity |
| TUBB (isotype panel) | Human beta-tubulin isotypes | Predictive factor for tubulin-binding agents |
| TUBB (Alzheimer context) | Brain beta-tubulin | Exchangeable GTP site changes in Alzheimer disease |
How Is beta-tubulin binding Regulated?
Beta-tubulin binding is regulated at multiple levels. The exchangeable GTP binding site of the beta-subunit modulates beta-tubulin behavior and has been studied in Alzheimer disease brain tissue. Beta-tubulin isotype expression levels influence ligand binding and drug response, as shown for beta-III tubulin and indibulin neurotoxicity. Mutations in beta-tubulin can alter binding of paclitaxel and contribute to chemotherapy resistance. In addition, proteins such as tau bind neuronal-specific beta-tubulin isotypes with differential affinity, providing a regulatory interaction layer.
beta-tubulin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TUBB3 | Chemotherapy neurotoxicity and drug response | TUBB3 knockout or overexpression in neuronal and cancer cell lines |
| TUBB | Paclitaxel resistance | Point-mutation knock-in of beta-tubulin mutations |
| MAPT | Neurodegeneration and tauopathy | MAPT knockout or tau repeat knock-in for beta-tubulin binding studies |
| TUBB (GTP site) | Alzheimer disease | Knock-in of GTP-site variants in neuronal models |
| TUBB (fungal) | Fungal infection biology | Heterologous expression of fungal beta-tubulin for zoxamide binding |
Cancer and tubulin-binding agent response
Beta-tubulin binding is directly relevant to cancer therapy because tubulin-binding agents target beta-tubulin. Class III beta-tubulin has been evaluated as a predictive factor in patients receiving tubulin-binding agents. Mutations in beta-tubulin can change paclitaxel binding and contribute to chemotherapy resistance. Beta-III tubulin levels determine the neurotoxicity induced by the colchicine-site binding agent indibulin.
Neurotoxicity of microtubule-targeting drugs
The neurotoxicity of colchicine-site binding agents depends on beta-III tubulin levels, linking beta-tubulin binding to peripheral neurotoxicity observed during chemotherapy. This connection makes beta-tubulin isotype profiling relevant to predicting adverse effects of tubulin-binding agents.
Neurodegeneration and Alzheimer disease
The exchangeable GTP binding site of the beta-subunit of brain tubulin has been examined in Alzheimer disease, suggesting that beta-tubulin nucleotide-site function is altered in this condition. Tau, a microtubule-associated protein implicated in neurodegeneration, binds neuronal-specific beta-tubulin isotypes with differential affinity through its repeat region R2.
Fungal pathogens and antimicrobial targeting
Covalent binding of zoxamide to beta-tubulin of Botrytis cinerea demonstrates that beta-tubulin binding is also a mechanism of antifungal action. This extends the relevance of GO:0048487 beyond human disease to agricultural and infectious contexts.
From beta-tubulin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a beta-tubulin binding protein alter microtubule dynamics? | CRISPR knockout cell line |
| Does a specific beta-tubulin mutation change drug binding? | Point-mutation knock-in |
| Does a disease-associated beta-tubulin variant affect ligand interactions? | Knock-in of mutant beta-tubulin |
| Where does a beta-tubulin binding protein localize? | Tagged knock-in with fluorescent tag |
| Does overexpression of beta-III tubulin increase neurotoxicity? | Overexpression cell model |
| Can beta-tubulin binding be measured in live cells? | Tagged knock-in and imaging |
How to Study the beta-tubulin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Colchicine-binding assay | Binding to the colchicine site of beta-tubulin | Characterizing beta-tubulin ligands |
| Molecular dynamics (MD) | Ligand binding modes and stability | Cabazitaxel and paclitaxel binding studies |
| DFT calculations | Electronic properties of ligand-tubulin interactions | Cabazitaxel binding mode analysis |
| GTP binding assays | Exchangeable GTP site occupancy | Alzheimer disease brain tubulin studies |
| Covalent binding assays | Irreversible modification of beta-tubulin | Zoxamide binding to fungal beta-tubulin |
| Isotype-specific binding assays | Affinity for different beta-tubulin isotypes | Tau R2 binding studies |
| Neurotoxicity assays | Cellular toxicity of tubulin-binding agents | Indibulin and beta-III tubulin studies |
| Clinical correlation analysis | Association of beta-tubulin isotypes with drug response | Predictive factor evaluation |
Binding assays and structural modeling
Biochemical analysis of the colchicine-binding site of beta-tubulin established key ligand interactions. Computational approaches such as DFT and MD simulations have been used to study cabazitaxel binding modes with different human beta-tubulin isotypes. Molecular simulations of paclitaxel binding to mutant beta-tubulin provide insights into chemotherapy resistance.
Isotype-specific interaction studies
Differential binding affinity of tau repeat region R2 with neuronal-specific beta-tubulin isotypes has been measured to understand isotype selectivity. Beta-III tubulin levels have been linked to neurotoxicity of indibulin, providing a functional readout of isotype-dependent binding.
GTP-site and disease-tissue analysis
The exchangeable GTP binding site of the beta-subunit of brain tubulin has been analyzed in Alzheimer disease, illustrating how nucleotide-site binding can be studied in disease tissue. Such analyses connect beta-tubulin binding to neurodegeneration.
Covalent binding and antifungal studies
Molecular insights into covalent binding of zoxamide to beta-tubulin of Botrytis cinerea demonstrate methods for studying covalent beta-tubulin binders. These approaches are relevant to both antifungal discovery and understanding covalent mechanisms.
How CRISPR Can Be Used to Study GO:0048487 beta-tubulin binding
Knockout
CRISPR knockout of beta-tubulin binding-related genes can test whether a candidate protein is required for microtubule-dependent processes. For example, knocking out TUBB3 or MAPT can reveal effects on drug sensitivity and microtubule stability, building on evidence that beta-III tubulin levels determine indibulin neurotoxicity and that tau binds neuronal beta-tubulin isotypes.
Point Mutation
Point-mutation models can introduce specific beta-tubulin residues to test how mutations alter ligand binding. Simulations of paclitaxel binding to mutant beta-tubulin provide a rationale for selecting residues that affect chemotherapy resistance. Such models help validate structural predictions from colchicine-site and taxane-site studies.
Knock-in
Knock-in of disease-associated or isotype-specific beta-tubulin variants allows study of beta-tubulin binding in a native context. This is relevant to Alzheimer disease-related GTP-site changes and to isotype-specific drug interactions.
Overexpression
Overexpression of beta-tubulin isotypes or binding partners can test gain-of-function effects on drug response and neurotoxicity. Beta-III tubulin overexpression is particularly relevant because beta-III tubulin levels determine indibulin neurotoxicity and class III beta-tubulin is a predictive factor for tubulin-binding agents.
How EDITGENE Supports beta-tubulin binding Research
Researchers studying beta-tubulin binding-related genes often need to determine whether a candidate gene is causally involved in microtubule regulation, drug response, or neurotoxicity. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses directly.
Contact EDITGENE today to design your custom CRISPR model for beta-tubulin binding research.
Frequently Asked Questions About beta-tubulin binding
What is GO:0048487 beta-tubulin binding?
GO:0048487 beta-tubulin binding is a Gene Ontology molecular function defined as binding to the microtubule constituent protein beta-tubulin.
What genes are involved in beta-tubulin binding?
Genes encoding beta-tubulin isotypes such as TUBB, TUBB3, TUBB2B, TUBB4A, and TUBB1, as well as MAPT encoding tau, are relevant to beta-tubulin binding.
Why is beta-tubulin binding important in cancer?
Beta-tubulin binding is the mechanism of action of tubulin-binding agents, and class III beta-tubulin is a predictive factor in patients receiving these drugs.
How do mutations in beta-tubulin affect drug binding?
Molecular simulations show that mutations in beta-tubulin can alter paclitaxel binding and provide insights into chemotherapy resistance.
What is the colchicine-binding site of beta-tubulin?
The colchicine-binding site is a specific pocket on beta-tubulin that has been analyzed as a ligand-binding site for colchicine-site agents.
Is beta-tubulin binding involved in Alzheimer disease?
The exchangeable GTP binding site of the beta-subunit of brain tubulin has been studied in Alzheimer disease, linking beta-tubulin nucleotide-site function to the disease.
How does tau bind beta-tubulin?
The tau repeat region R2 shows differential binding affinity with neuronal-specific beta-tubulin isotypes.
What methods are used to study beta-tubulin binding?
Methods include colchicine-binding assays, molecular dynamics, DFT calculations, GTP binding assays, and covalent binding assays.
Can CRISPR be used to study beta-tubulin binding?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can test the causal roles of beta-tubulin binding-related genes.
What is the role of beta-III tubulin in neurotoxicity?
Beta-III tubulin levels determine the neurotoxicity induced by the colchicine-site binding agent indibulin.
Conclusion
GO:0048487 beta-tubulin binding defines a molecular function that is central to microtubule biology, drug action, and disease. The colchicine-binding site and exchangeable GTP site of beta-tubulin are key structural determinants, and isotype-specific interactions influence drug response and neurotoxicity. Mutations in beta-tubulin can alter ligand binding and contribute to chemotherapy resistance, while tau-beta-tubulin interactions link this function to neurodegeneration. CRISPR-based models provide a direct way to test the causal roles of beta-tubulin binding-related genes in these contexts.
References
- 1. Kumari A et al.. 2023. β-III Tubulin Levels Determine the Neurotoxicity Induced by Colchicine-Site Binding Agent Indibulin.. ACS Chem Neurosci 14(1):19-34 PMID: 36541944
- 2. Burns RG. 1992. Analysis of the colchicine-binding site of beta-tubulin.. FEBS Lett 297(3):205-8 PMID: 1544399
- 3. Sève P et al.. 2008. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol 9(2):168-75 PMID: 18237851
- 4. Zhu L et al.. 2020. Binding modes of cabazitaxel with the different human β-tubulin isotypes: DFT and MD studies.. J Mol Model 26(6):162 PMID: 32474655
- 5. Khatoon S et al.. 1989. Exchangeable GTP binding site of the beta-subunit of brain tubulin in Alzheimer disease.. Prog Clin Biol Res 317:801-7 PMID: 2690125
- 6. Velasco-Saavedra MA et al.. 2023. Molecular Insights into the Covalent Binding of Zoxamide to the β-Tubulin of Botrytis cinerea.. J Chem Inf Model 63(20):6386-6395 PMID: 37802126
- 7. Vottero P et al.. 2025. Molecular simulations of paclitaxel binding to mutant β-tubulin: insights into chemotherapy resistance.. J Comput Aided Mol Des 40(1):17 PMID: 41388181
- 8. Bhandare VV et al.. 2019. Differential binding affinity of tau repeat region R2 with neuronal-specific β-tubulin isotypes.. Sci Rep 9(1):10795 PMID: 31346240
